Education
About Us
Working with TipRanks
Follow Us
XBI - ETF AI Analysis
Top Page
SPDR S&P BIOTECH ETF (XBI)
Rating:59Neutral
Price Target:―
Positive Factors
Strong Recent Top Holdings
Several of the largest positions, such as Revolution Medicines and Moderna, have shown strong year-to-date gains, helping support the fund’s overall performance.
Broad Biotech Stock Spread
The top holdings each make up only a small slice of the fund, which helps reduce the impact if any single biotech company runs into trouble.
Moderate Expense Ratio
The fund’s fee is reasonable for a specialized biotech ETF, allowing investors to keep more of any potential returns.
Negative Factors
Highly Concentrated in One Sector
Almost all assets are in health care and specifically biotech, so the fund is very sensitive to swings in that single industry.
Limited Geographic Diversification
With nearly all holdings in U.S. companies, investors are heavily exposed to the U.S. biotech market and regulatory environment.
Choppy Short-Term Performance
Recent returns have been mixed, with a weak one-month period despite stronger three-month performance, showing that the fund can be volatile over short time frames.
XBI vs. SPDR S&P 500 ETF (SPY)
AUM8.00B
RegionNorth America
Expense Ratio0.35%
Beta1.01
IssuerSPDR
Inception DateJan 31, 2006
Dividend Yield0.35%
Asset ClassEquity
Index TrackedS&P Biotechnology Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume7,119,359
30 Day Avg. Volume9,227,161
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
194.08Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering145
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XBI Summary
XBI is the SPDR S&P Biotech ETF, which follows the S&P Biotechnology Select Industry Index and focuses on U.S. biotechnology companies within the health care sector. It holds a wide mix of biotech firms, from smaller innovators to more familiar names like Moderna, all in roughly equal weights so no single company dominates. Someone might invest in XBI to bet on the long-term growth of new medicines, vaccines, and cutting-edge treatments, while spreading that bet across many companies. A key risk is that biotech stocks can be very volatile and can go up or down sharply based on drug trial results and market sentiment.
How much will it cost me?The SPDR S&P Biotech ETF (XBI) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This expense ratio is slightly higher than average because the fund is actively managed with an equal-weighted structure, which requires more frequent adjustments compared to passively managed ETFs.
What would affect this ETF?The SPDR S&P Biotech ETF (XBI) could benefit from advancements in biotechnology, such as breakthroughs in gene editing and personalized medicine, which drive innovation and growth in the sector. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding and investor sentiment in the biotech industry.
XBI Top 10 Holdings
XBI is a pure U.S. biotech play, and its story is all about volatile drug developers rather than steady blue chips. Rising names like Roivant, Mirum, and Praxis are giving the fund a lift, helped by upbeat trial news and deal activity. Established players Amgen, Gilead, and BioMarin are providing a steadier backbone, adding support without dominating the stage. On the flip side, Moderna and Revolution Medicines have been more mixed to lagging, occasionally pulling on performance. Thanks to its equal-weight design, no single stock drives the show, but biotech risk clearly does.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 2.07% | $167.46M | $18.21B | 40.36% | 59 Neutral | |
| Roivant Sciences | 1.64% | $133.01M | $19.67B | 154.21% | 58 Neutral | |
| Mirum Pharmaceuticals | 1.60% | $129.39M | $5.43B | 100.50% | 56 Neutral | |
| Revolution Medicines | 1.59% | $129.04M | $19.29B | 146.32% | 52 Neutral | |
| Vaxcyte | 1.59% | $128.93M | $7.97B | -26.62% | 50 Neutral | |
| Praxis Precision Medicines | 1.53% | $124.00M | $9.02B | 350.10% | 58 Neutral | |
| Gilead Sciences | 1.51% | $121.84M | $189.50B | 37.70% | 78 Outperform | |
| Amicus | 1.47% | $118.99M | $4.50B | 56.04% | 73 Outperform | |
| Amgen | 1.44% | $116.48M | $204.70B | 23.68% | 77 Outperform | |
| BioMarin Pharmaceutical | 1.43% | $115.54M | $11.88B | -6.11% | 75 Outperform |
XBI Technical Analysis
Positive
―
Price Trends
124.46
Positive
117.74
Positive
101.94
Positive
Market Momentum
0.12
Positive
49.62
Neutral
76.88
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XBI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 125.61, equal to the 50-day MA of 124.46, and equal to the 200-day MA of 101.94, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 49.62 is Neutral, neither overbought nor oversold. The STOCH value of 76.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XBI.
XBI Peer Comparison
Comparison Results
Performance Comparison
XBI
SPDR S&P BIOTECH ETF
124.78
35.01
39.00%
IBB
iShares Biotechnology ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents